Darunavir (Prezista)

An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Also Known As:

Prezista; TMC-114; Darunavir Ethanolate; TMC 114; TMC114; UIC-94017; UIC94017; 114, TMC; Ethanolate, Darunavir; UIC 94017; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester

Networked: 297 relevant articles (12 outcomes, 64 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Clotet, Bonaventura: 8 articles (06/2018 - 04/2007)
2.	Brown, Todd T: 6 articles (01/2022 - 10/2014)
3.	Gatanaga, Hiroyuki: 6 articles (09/2021 - 03/2012)
4.	Kikuchi, Yoshimi: 6 articles (09/2021 - 03/2012)
5.	Nishijima, Takeshi: 6 articles (09/2021 - 03/2012)
6.	Oka, Shinichi: 6 articles (09/2021 - 03/2012)
7.	Ghosh, Arun K: 6 articles (01/2021 - 10/2003)
8.	Molina, Jean-Michel: 5 articles (01/2020 - 04/2007)
9.	Ribera, Esteban: 5 articles (01/2020 - 11/2009)
10.	Currier, Judith S: 5 articles (02/2019 - 07/2012)

Related Diseases

1.	Infections 04/01/2020 - "Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection." 01/01/2014 - "Here we describe an analysis of effectiveness and durability data from two cohorts of DRV/r-experienced patients with HIV-1 infection, already receiving DRV/r according to usual clinical practice, collected prospectively from June 2009 to December 2012: Cohort 1, data from patients from the DRV/r Early Access Program (TMC114-C226 study; N=235 patients) and Cohort 2, a separate cohort of ARV-DRV/r-experienced patients (N=407 patients), treated with DRV/r in the market. " 01/01/2009 - "PHARMACOECONOMIC CONSIDERATIONS: Healthcare costs in the UK and US were estimated to be lower with boosted darunavir than with investigator-selected CPIs in treatment-experienced patients with HIV-1 infection in two 1-year cost analyses conducted from the perspective of a healthcare provider and using predicted costs based on CD4+ cell counts and clinical data from the POWER studies. " 01/01/2009 - "Boosted darunavir was generally well tolerated in patients with HIV-1 infection in clinical trials, with most events being mild to moderate in severity. " 01/01/2009 - "Boosted darunavir was generally well tolerated in patients with HIV-1 infection in clinical trials. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 09/05/2018 - "Darunavir (DRV) is an antiretroviral drug used to treat and prevent human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), but whether DRV is protective against CPT-11-induced intestinal toxicity is unclear. " 01/01/2021 - "No caso do darunavir, houve uma redução do preço global do medicamento, inclusive no preço do Fundo Global de Luta Contra aids, Tuberculose e Malária. " 12/15/2007 - "Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens." 01/01/2016 - "Prospective study in AIDS Clinical Trials Group A5303, a double-blind, placebo-controlled trial (N = 262) of MVC vs. TDF, each combined with boosted darunavir and emtricitabine. " 09/01/2023 - "Quality by design tool-evaluated stability-indicating ultra-performance liquid chromatography method for the determination of drugs (ritonavir and darunavir) used to treat the human immunodeficiency virus/acquired immunodeficiency syndrome."
3.	HIV Infections (HIV Infection) 01/01/2021 - "In July 2016, the FDA expanded the approval for use of darunavir in pregnant women with HIV infection. " 12/01/2018 - "Development of darunavir over the entire spectrum of HIV infection." 07/01/2018 - "Darunavir for the treatment of HIV infection." 03/01/2013 - "Subjects with HIV infection were selected based on the use of darunavir-containing regimens with a twice-daily dosing schedule and availability of stored CSF and matched plasma. " 01/01/2009 - "This review focuses on the role of darunavir in managing HIV infection, with an emphasis on darunavir's exceptional resistance profile and related clinical effectiveness, pharmacokinetics, tolerability and toxicity data. "
4.	Coinfection 10/01/2008 - "[Darunavir in HIV/HVC/HVB coinfection]." 04/01/2012 - "The MONET study, comparing darunavir/ritonavir-based triple therapy and monotherapy, has found higher risk of failure in patients with positive HCV serology, but the effects of HCV co-infection on the efficacy of antiretroviral treatment have not been clearly established. " 01/01/2022 - "While contemporary antiretrovirals pose less risk for ESLD than hepatitis coinfection, atazanavir and darunavir had a toxicity signal. " 07/01/2014 - "Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort." 07/01/2014 - "To investigate differences in liver enzyme elevation (LEE) between HIV-infected patients with and without HCV coinfection who start a darunavir/ritonavir-containing regimen. "
5.	Hepatitis B 07/01/2007 - "This subanalysis examines the safety and efficacy of darunavir with low-dose ritonavir (DRV/r) in hepatitis B or C virus (HBV or HCV) co-infected patients in POWER 1 and 3 trials. " 10/01/2008 - "In hepatitis B or C co-infected patients, the virological response rate to darunavir/ritonavir appeared to be unaffected and, except for increased liver enzymes, the incidence of adverse events was not higher than in patients without co-infection. " 07/01/2007 - "Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3." 07/01/2012 - "No significant differences between patients with and without virological failure were observed for gender, age, route of transmission, baseline CD4/HIV-RNA, CDC group, hepatitis B or C co-infections, resistance (based on the last genotype available), type and number of concomitant drug classes, concomitant use of darunavir, atazanavir, etravirine, enfuvirtide or maraviroc, and health-related quality-of-life measures. " 11/01/2010 - "This issue focuses on the following selection of drugs: Abatacept, Adalimumab, AdCD40L, Adefovir, Aleglitazar, Aliskiren fumarate, AM-103, Aminolevulinic acid methyl ester, Amlodipine, Anakinra, Aprepitant, Aripiprazole, Atazanavir sulfate, Axitinib; Belimumab, Bevacizumab, Bimatoprost, Bortezomib, Bupropion/naltrexone; Calcipotriol/betamethasone dipropionate, Certolizumab pegol, Ciclesonide, CYT-997; Darbepoetin alfa, Darunavir, Dasatinib, Desvenlafaxine succinate, Dexmethylphenidate hydrochloride cogramostim; Eltrombopag olamine, Emtricitabine, Escitalopram oxalate, Eslicarbazepine acetate, Eszopiclone, Etravirine, Everolimus-eluting coronary stent, Exenatide, Ezetimibe; Fenretinide, Filibuvir, Fludarabine; Golimumab; Hepatitis B hyperimmunoglobulin, HEV-239, HP-802-247, HPV-16/18 AS04, HPV-6/11/16/18, Human albumin, Human gammaglobulin; Imatinib mesylate, Inotuzumab ozogamicin, Invaplex 50 vaccine; Lapatinib ditosylate, Lenalidomide, Liposomal doxorubicin, Lopinavir, Lumiliximab, LY-686017; Maraviroc, Mecasermin rinfabate; Narlaprevir; Ocrelizumab, Oral insulin, Oritavancin, Oxycodone hydrochloride/naloxone; Paclitaxel-eluting stent, Palonosetron hydrochloride, PAN-811, Paroxetine, Pazopanib hydrochloride, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Pitavastatin calcium, Posaconazole, Pregabalin, Prucalopride succinate; Raltegravir potassium, Ranibizumab, RHAMM R3 peptide, Rosuvastatin calcium; Salclobuzic acid sodium salt, SCY-635, Selenate sodium, Semapimod hydrochloride, Silodosin, Siltuximab, Silybin, Sirolimus-eluting stent, SIR-Spheres, Sunitinib malate; Tapentadol hydrochloride, Tenofovir disoproxil fumarate, Tocilizumab, Tositumomab/iodine (I131) tositumomab, Trabectedin, TransVax™ hepatitis C vaccine; Ustekinumab; V-260, Valspodar, Varenicline tartrate, VCL-IPT1, Vildagliptin, VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, VRC-HIVDNA016-00-VP; Yttrium 90 (90Y) ibritumomab tiuxetan, Yttrium Y90 Epratuzumab; Zibotentan, Zotarolimus-eluting stent."

Related Drugs and Biologics

1.	Ritonavir (Norvir)
2.	Raltegravir Potassium
3.	Atazanavir Sulfate (Reyataz)
4.	Lopinavir
5.	dolutegravir
6.	Protease Inhibitors (Protease Inhibitor)
7.	Darunavir (Prezista)
8.	Integrase Inhibitors
9.	elvitegravir
10.	favipiravir

Related Therapies and Procedures

1.	Therapeutics
2.	Inhalation Administration
3.	Art Therapy
4.	Pain Management
5.	Highly Active Antiretroviral Therapy (HAART)